In afternoon trade on Friday, the S&P/ASX 200 Index (ASX: XJO) is on course to record a decent gain. At the time of writing, the benchmark index is up 0.4% to 8,574.7 points.
Four ASX shares that are rising more than most today are listed below. Here's why they are charging higher:
The GQG Partners share price is up 5.5% to $2.50. This morning, this investment company released its full year results and revealed a strong set of numbers. GQG Partners posted a 46.9% increase in net revenue to US$760.4 million and a 50.4% jump in distributable earnings to US$447.9 million. GQG Partners' CEO and executive director, Tim Carver, said: "The growth in FUM reflects strong performance from our investment team and another great effort from our business team. The increase in FUM led to net revenue growth of 46.9% to US$760.4 million during 2024. Net operating income increased 50.4% to US$577.9 million during the same period, reflecting an increase in average funds under management partially offset by an increase in expenses as GQG continues to invest in talent and overall business activities."
The Imugene share price is up 10% to 4.3 cents. This follows the release of a trial update from the clinical-stage immuno-oncology company. Imugene revealed more positive results from its Phase 1b clinical trial evaluating azer-cel in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Chief Medical Officer Dr Paul Woodard said: "All four Complete Responses in Cohort B were achieved in patients who had failed at least 4 lines of therapy in this hard-to-treat population, including autologous CAR T therapy. This suggests that azer-cel, in combination with IL-2, may offer a meaningful therapeutic option where other treatments have not succeeded."
The Mirvac share price is up 4% to $2.08. Investors have been buying the property company's shares following the release of its half year results. Mirvac reported an operating profit of $236 million, which represents 6 cent per share. As a result, the company is on track to deliver on its full year guidance of between 12 cents to 12.3 cents per share in FY 2025.
The Temple & Webster share price is up a further 8% to $17.45. Investors have been bidding the furniture and homeware retailer's shares higher this week following the release of its half year results. Temple & Webster reported a 23.6% increase in revenue to $313.7 million and a 118% jump in net profit after tax to $9 million. The company's CEO, Mark Coulter, said: "Temple & Webster has again delivered a record half, with strong performance against all key metrics, against a challenging macro and consumer backdrop."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.